Detalhe da pesquisa
1.
Kidney stone formation in a novel murine model of polycystic kidney disease.
Am J Physiol Renal Physiol
; 323(1): F59-F68, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35343849
2.
Contribution of phosphate and FGF23 to CKD progression.
Curr Opin Nephrol Hypertens
; 31(4): 306-311, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35283435
3.
Dietary phosphate restriction attenuates polycystic kidney disease in mice.
Am J Physiol Renal Physiol
; 318(1): F35-F42, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682174
4.
Trimethylamine-N-oxide acutely increases cardiac muscle contractility.
Am J Physiol Heart Circ Physiol
; 318(5): H1272-H1282, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32243768
5.
Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice.
Drug Metab Dispos
; 46(9): 1304-1309, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29915157
6.
Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.
J Am Soc Nephrol
; 27(1): 305-13, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26229137
7.
Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
Br J Nutr
; 116(12): 2074-2081, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28065190
8.
FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.
Am J Physiol Endocrinol Metab
; 307(5): E426-36, 2014 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25053401
9.
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.
Am J Physiol Endocrinol Metab
; 304(8): E863-73, 2013 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23443925
10.
Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
Kidney Int
; 84(4): 713-21, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23698235
11.
Is fibroblast growth factor 23 a harbinger of mortality in CKD?
Pediatr Nephrol
; 27(5): 697-703, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21390563
12.
Correction of Vascular Calcification and Hyperphosphatemia in CKD Rats Treated with ASARM Peptide.
Kidney360
; 3(10): 1683-1698, 2022 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36514737
13.
Critical Role of Osteopontin in Maintaining Urinary Phosphate Solubility in CKD.
Kidney360
; 3(9): 1578-1589, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36245654
14.
Caspase-1 and the inflammasome promote polycystic kidney disease progression.
Front Mol Biosci
; 9: 971219, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36523654
15.
Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
Semin Dial
; 24(3): 298-306, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21682772
16.
Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.
J Am Soc Nephrol
; 21(2): 353-61, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20007751
17.
Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Rep
; 6(4): 953-961, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33912745
18.
Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD.
Kidney360
; 1(11): 1206-1216, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34322673
19.
Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?
Nephrol News Issues
; 23(6): 33-4, 36-7, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19534362
20.
Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease.
J Pharm Biomed Anal
; 174: 618-624, 2019 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31276982